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BRCA testing for all newly-diagnosed breast cancer patients? 
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Breast cancer patients with BRCA1/2-driven tumors may benefit from targeted therapy. It is 
not clear whether current BRCA screening guidelines are effective at identifying these patients. The 
purpose of this study was to evaluate the prevalence of inherited BRCA1/2 pathogenic variants in a 
large, clinically representative breast cancer cohort and to estimate the proportion of BRCA1/2 
carriers not detected by selectively screening individuals with the highest probability of being carriers 
according to current clinical guidelines. The study included 5,122 unselected Swedish breast cancer 
patients diagnosed from 2001 to 2008. Target sequence enrichment (48.48 Fluidigm Access Arrays) 
and sequencing were performed (Illumina Hi-Seq 2500 instrument, v4 chemistry). Differences in 
patient and tumor characteristics of BRCA1/2 carriers who were already identified as part of clinical 
BRCA1/2 testing routines and additional BRCA1/2 carriers found by sequencing the entire study 
population were compared using logistic regression models. Ninety-two of 5,099 patients with valid 
variant calls were identified as BRCA1/2 carriers by screening all study participants (1.8%). Only 416 
study participants (8.2%) were screened as part of clinical practice, but this identified 35 out of 92 
carriers (38.0%). Clinically-identified carriers were younger, less likely postmenopausal and more 
likely to be associated with familiar ovarian cancer compared to the additional carriers identified by 
screening all patients. More BRCA2 (34/42, 81.0%) than BRCA1 carriers (23/50, 46%) were missed 
by clinical screening. In conclusion, BRCA1/2 mutation prevalence in unselected breast cancer 
patients was 1.8%. Six in ten BRCA carriers were not detected by selective clinical screening of 
individuals.  
NOVELTY AND IMPACT 




Estimates of the prevalence of BRCA1 or BRCA2 germline pathogenic variants vary 
considerably depending on the technology used for mutation screening, population size, and to what 
extent the genes are tested 1. Although BRCA1/2 pathogenic variants are major determinants of 
hereditary breast cancers, women diagnosed with BRCA1/2-associated breast cancer do not 
necessarily exhibit worse survival patterns than breast cancer patients without such pathogenic 
variants 2. On the contrary, patients diagnosed with BRCA1/2-associated breast cancers have 
advantages in terms of treatment options when compared to patients with BRCA1/2 wild-type breast 
cancer (reviewed in 3). Evidence from clinical trials showed significantly greater sensitivity and higher 
response rate of BRCA1/2-associated cancers to neoadjuvant and standard adjuvant chemotherapy 
than their wild-type BRCA1/2 counterparts 3. Treatment options for BRCA1/2 breast cancers are also 
broadened with the introduction of new therapeutic agents, such as poly (ADP-ribose) polymerase 
(PARP) inhibitors, which selectively target BRCA1/2-deficient cancer cells 4-7.  
Recommendation for counselling and genetic screening for BRCA1/2 pathogenic variants is 
mainly based on personal and family history of breast and/or ovarian cancer, young age at disease 
onset, male breast cancer and multiple tumors (bilateral breast cancer or breast and ovarian cancer in 
the same patient) 8. However, BRCA testing guidelines vary by region and country 9, 10. In Sweden, 
the Swedish Breast Cancer Group BRCA1 and BRCA2 screening criteria are used 8. A report by 
Nilsson et al. estimated that the Swedish BRCA testing criteria has an effectiveness of only 18% and 
concluded that clinical genetic testing criteria for BRCA1 and BRCA2 should be critically revised 8. As 
the effective identification of BRCA1/2 germline pathogenic variants has potential to influence 
treatment decision and has implications for the family of the patients 3-6, 11, 12, the pros and cons of 
testing all women diagnosed with breast cancer for such pathogenic variants need to be examined. In 
a large, clinically representative breast cancer cohort, we examined the prevalence and 
characteristics of BRCA1/2 germline mutation carriers and compared our results with BRCA mutation 






All women under the age of 80 and diagnosed with breast cancer from 2001 to 2008 in 
Stockholm, Sweden were identified through the Stockholm-Gotland Regional Breast Cancer quality 
register 13, 14. Women were invited to participate in the LIBRO1 study in 2009. In all, 5,715 women of 
the LIBRO1 study gave informed consent to the retrieval of data from medical records and national 
registers, answered a detailed questionnaire on background and lifestyle risk factors, and provided a 
blood specimen for genetic analysis 13, 14. Of these women, 5,125 were successfully genotyped in a 
large-scale genotyping study on breast cancer risk (see eTable 1 in Data Supplement 1 for exclusion 
criteria, online only) 15. Of these women, 5,122 had enough DNA remaining for targeted sequencing. 
The final analytical dataset comprised 5,099 samples which passed quality control. This study was 
approved by the Regional Ethical Review Board in Stockholm, Sweden (Karolinska Institutet, 
DNR2009/254-31/4). 
Patient characteristics 
 Self-reported information on education level, age at menarche, body mass index (BMI), 
number of children, oral contraceptive use, hormone replacement therapy, and details of family 
history of breast and ovarian cancer were obtained from the questionnaire. Patients were asked if 
their biological mothers and sisters have been diagnosed with breast or ovarian cancer, and if so, at 
what age. Mammograms were retrieved from radiology departments. Percent mammographic density 
was measured using an automated method described in 16. Information on whether the patients have 
an ovarian cancer or any non-breast malignancy was retrieved via linkage to the Swedish Cancer 
Register using unique personal identity numbers of study participants (personnummer, ten or twelve 
digit number used in Sweden to identify individuals) 17.  
Tumor characteristics 
Tumor characteristics were retrieved from the Stockholm-Gotland Regional Breast Cancer 
Quality Register 18, 19 using unique personal identity numbers 17. Tumor size was measured in 
millimetres. Lymph node involvement was dichotomized into positive or negative. Estrogen receptor 
(ER) status was recorded as negative or positive in the registers, determined by radioimmunoassay or 
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immunohistochemistry with cutoff values of more than 10% positive cells for IHC and more than 0 
fmol/μg DNA for radioimmunoassay assays. The completeness of the registry data was 98% for tumor 
size and lymph node status and 80% for ER status. Information on grade (Nottingham histologic 
grade for invasive cancer and nuclear grade for cancer in situ) was available from 2004, with 93% 
completeness 19. 
Data on molecular markers were retrieved in 2015–2016 from medical and pathology records 
at treating hospitals (previously described in 20). HER2 status was dichotomized (positive/negative) in 
accordance with the Swedish Society of Pathology's guidelines: negative if protein expression showed 
0 or 1+, or was higher with no confirmed gene amplification by FISH, and positive if FISH showed 
gene amplification.20 Proliferation marker Ki67 was measured according to contemporary guidelines 
and reported as percent staining (low if <20% and high otherwise).20 HER2 and Ki67 markers were 
not assessed, and thus not available in medical records, prior to 2005. Breast cancer subtype was 
assigned using a random forest algorithm (caret R package, v. 6.0.58) described in 20. The algorithm 
was trained to predict subtype based on a subset of individuals with PAM50 subtype derived from 
gene expression data (n=237). Breast cancer subtype was then assigned to the remaining cases 
based on age at diagnosis, ER, PR, HER2, and Ki67 status. 
Targeted sequencing and data processing 
Target-enriched sequencing libraries of germline DNA from 5,122 breast cancer patients were 
prepared at the Centre for Cancer Genetic Epidemiology (University of Cambridge), as part of a larger 
effort that included samples from other cohorts. Briefly, target sequence enrichment was performed 
using 48.48 Fluidigm Access Arrays according to the manufacturer’s protocol (Fluidigm, South San 
Francisco, California, USA). Fluidigm D3 assay design software was used to select primer pairs, 
which were multiplexed into pools selected for GC content and avoidance of off-target primer-primer 
and primer-product complementarity (eTable 2 in Data Supplement 2). Target sequences were 
amplified with Illumina sequencing adaptors and one of 1,536 unique sample barcodes (supplied by 
Fluidigm, South San Francisco, California, USA). Robotic liquid handling and barcode plate 
identification were used in all steps of the library preparation process. The amplicon library was 
quantified with the KAPA Library Quantification Kit (KapaBiosystems, Boston, Massachusetts, USA) 
and then sequenced on the Illumina Hi-Seq 2500 instrument using v4 chemistry, according to the 
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manufacturer’s protocol (Illumina, San Diego, California, USA). Each library was sequenced 2-3 times 
to provide sufficient coverage. Details on sequence data processing and quality control are shown in 
eMethods in Data Supplement 1. A total of 5,099 samples had valid variant calls. The mean read 
depth across the coding sequences of BRCA1 and BRCA2 was 792.2 (standard deviation: 587.4) and 
631 (standard deviation: 516), respectively. More than 90% of targeted bases had more than 15x 
coverage (94.8 [15.9] and 92.5 [20.4] for BRCA1 and BRCA2, respectively). 
Definition of pathogenic variants 
As described previously in Borg et al. 21, sequence variants were categorized based on their 
predicted effect on the mRNA and amino acid level and defined as pathogenic if they were (1) 
frameshift and nonsense variants with the exception of the BRCA2 c.9976A>T (BIC: K3326X) and 
other variants located 3’ thereof (n=105), and (2) all consensus splice acceptor or donor sequence 
sites, except those predicted to lead to naturally occurring in-frame RNA isoforms that may rescue 
gene function 22. Public data on pathogenic BRCA variants (includes frameshift insertion/deletions, 
nonsense, splice sites and missense variants conclusively demonstrated to be pathogenic) that have 
been curated and classified by an international expert panel, the ENIGMA consortium, were also 
downloaded from http://brcaexchange.org/ (access date: Feb 22, 2017) for the annotation of the 
sequence data. 
Identification of women who have undergone BRCA testing in Sweden 
Mutation screening for all oncogenetic clinics in Sweden (Lund, Stockholm, Uppsala, 
Göteborg, Linköping and Umeå) were conducted at the Department of Oncology, Lund University as 
part of a national BRCA testing program (eMethods in Data Supplement 1). We cross-referenced 
the personal identity numbers of all study participants in LIBRO1 with the BRCA testing unit at Lund 
University to identify women who have been tested for BRCA1/2 pathogenic variants previously. The 
SweBRCA criteria are the only BRCA1/2 testing criteria used in Sweden (eTable 3 in Data 
Supplement 1) 8. Clinicians do not have any obligation to comply with the guidelines 8. 
Statistical analysis 
Predictor variables which include patient and tumor characteristics were described by the 
counts of each category and corresponding proportions. Binary logistic regression models were fitted 
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for the dichotomous outcome (BRCA1 [reference] and BRCA2), and multinomial logistic regression 
models were fitted for the three-category outcome (BRCA1, BRCA2 and non-BRCA [reference 
category]), adjusting for age and year of diagnosis. Logistic regression models were also used to 
compare estimates (odds ratios [OR] and corresponding 95% confidence intervals [CI]) of patient and 
tumor characteristics between BRCA1/2 carriers already identified among a subset of 416 patients 
screened as part of clinical BRCA testing routines and additional BRCA1/2 carriers found by 
sequencing the entire study population (i.e. those not tested by the Swedish BRCA testing program).  
RESULTS 
The median time from date of diagnosis to study entry is 4.8 years (range: 1.3 to 9.2). The 
median age of breast cancer diagnosis of the study cohort was 59.6 years (range: 25.1 to 79.9). Nine 
of ten breast cancers were invasive (89.4%). 
Spectrum of BRCA1 and BRCA2 pathogenic variants 
Of the 5,099 breast cancer patients, 92 (1.8%) were identified as BRCA1/2 carriers (50 
BRCA1 carriers and 42 BRCA2 carriers) and 5,007 were non-BRCA. 
Among the 50 BRCA1 carriers, there were 28 unique germline BRCA1 pathogenic variants 
(11 frameshift deletions, 2 frameshift insertions, 8 truncating, 4 splice sites, and 3 missense) (Figure 
1 and eTable 4 in Data Supplement 1). Frameshift insertions and deletions made up 26/50 (52%) of 
the BRCA1 pathogenic variants. Exon 11 harbored 33/50 (66%) of the BRCA1 pathogenic variants. 
The most common pathogenic variant was c.3048_3052dupTGAGA (n=8), which is a founder 
mutation originating from the West coast of Sweden 23. Three other Swedish founder pathogenic 
variants were also identified (c.1082_1092del [n=5], c.2475delC [n=2]) and c.3626delT [n=3]) 23-26. 
Among the 42 BRCA2 carriers, there were 33 unique BRCA2 pathogenic variants (18 
frameshift deletions, 3 frameshift insertions, 9 truncating, and 3 splice sites) (Figure 2 and eTable 5 
in Data Supplement 1, only online). Over half of all BRCA2 carriers (24/42, 57.1%) had a pathogenic 
variant on exon 11. 
Patient characteristics of non-BRCA, BRCA1 and BRCA2 carriers 
 Half of the non-BRCA women were at least 60 years old, compared to 26.0% and 33.3% for 
women with BRCA1 and BRCA2 pathogenic variants, respectively (eTable 6 in Data Supplement 1). 
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In the crude analyses controlling for age and year of diagnosis, BRCA1 and BRCA2 carriers were 
more likely than non-BRCA women to report family history of both breast (ORBRCA1 vs non-BRCA: 4.00 
[2.27 to 7.05] and ORBRCA2 vs non-BRCA:  2.23 [1.17 to 4.26]) and family history of ovarian cancer 
(ORBRCA1 vs non-BRCA: 7.53 [3.82 to 14.82] and ORBRCA2 vs non-BRCA: 3.62 [1.50 to 8.71]) (eTable 6 in Data 
Supplement 1). BRCA1 carriers, in particular, were also more likely to be also diagnosed with an 
ovarian cancer themselves (ORBRCA1 vs non-BRCA: 28.02 [10.72 to 73.29] and ORBRCA2 vs non-BRCA: 8.11 
[1.87 to 35.24]) than non-BRCA patients (eTable 6 in Data Supplement 1). BRCA1 carriers were 
more likely to have a personal history of another malignant cancer in addition to their breast cancer 
than patients with non-BRCA patients (ORBRCA1 vs non-BRCA: 2.93 [1.37 to 6.27]). This association was 
driven by ovarian cancers (ORBRCA1 vs non-BRCA for all non-breast and non-ovarian malignancies: 0.83 
[0.25 to 2.73]). BRCA2 carriers were significantly less likely to be ever users of hormone replacement 
therapy (HRT) than non-BRCA breast cancer patients (26.2% vs 53.8%) (eTable 6 in Data 
Supplement 1). In multivariable models shown in Table 1, all variables remained significantly 
associated, with the exception of personal history of any non-breast malignancy. 
Tumor characteristics of non-BRCA, BRCA1 and BRCA2 carriers 
In the crude analyses controlling for age and year of diagnosis, BRCA2 carriers were in 
general not significantly different from non-BRCA women in terms of tumor characteristics, with the 
exception of nodal involvement (ORBRCA2 vs non-BRCA: 2.71 [1.31 to 5.62], eTable 7 in Data Supplement 
1). On the contrary, tumors of BRCA1 carriers were more aggressive than those of non-BRCA breast 
cancer patients for all tumor characteristics examined (ER and PR status, grade, tumor size, nodal 
involvement, and breast cancer subtype) except for the proportion of invasive tumors (eTable 7 in 
Data Supplement 1).  
In multivariable multinomial models including all tumor characteristics that were significantly 
different between non-BRCA and BRCA1-positive breast cancer patients, only ER-negativity 
remained significant (ORBRCA1 vs non-BRCA: 5.19 [2.68 to 10.06]) (Table 1). ER status was also the only 
independent tumor characteristic that distinguished between BRCA1 and BRCA2 carriers (ORBRCA2 vs 
BRCA1: 0.22 [0.07 to 0.77]). This observation was mirrored in a separate multinomial model considering 
breast cancer subtypes, where BRCA1 tumors were found to be 40 times more likely to be of the 
basal-like subtype (ORBRCA1 vs non-BRCA: 40.07 [14.26 to 112.59]). Only nodal involvement remained 
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significant in the comparison between BRCA2 and non-BRCA breast cancer cases in the 
multivariable model (ORBRCA2 vs non-BRCA: 2.54 [1.20 to 5.37) (Table 1). 
Comparison of BRCA1/2 carriers identified versus not identified through clinical screening 
Linkage with the Swedish BRCA register found 416 patients (8.2%) that were screened for 
pathogenic variants as part of routine clinical practice. Among these 416 women, clinical screening 
identified 39 carriers in the study cohort, of which our study confirmed 35 (Figure 3). Four pathogenic 
variants were missed (BRCA1:  c.4186-1785_4358-1667dup and c.4358-1729_4986+736dup; 
BRCA2: c.7805+1538_8331+560del and c.9097_9098insT) (Figure 3). Three of these were large 
exonic deletions or duplications that the Fluidigm Access Array system is not suitable for detecting. 
This gives the Fluidigm Access Array method an estimated sensitivity of about 90%, or 97% when 
excluding large exonic variants.  
Overall, 57/92 carriers (62.0%) were not already clinically identified: Two additional carriers 
were detected by the Fluidigm Access Array method among clinically screened patients (BRCA2: 
c.2578delA [confirmed by Sanger sequencing to be a false positive] and c.7443delT [missed carrier, 
screened with DHPLC and MLPA in 2008]); the remaining 55 out of 92 carriers (59.8%) identified by 
the Fluidigm Access Array method in the complete study cohort were never screened as part of 
clinical routine (Figure 3). 
More BRCA2 (34/42, 80%) than BRCA1 pathogenic variants (23/50, 46%) were missed by 
selectively testing only high-risk individuals who were recommended for genetic testing and 
counselling (Table 2). Controlling for only year of diagnosis, BRCA carriers identified by clinical 
routine screening were younger (37.2% aged 50 years and above, compared to 73.7%), less likely to 
have experienced menopause (ORidentified versus not identified: 0.17 [0.07 to 0.44]) and more likely to be 
associated with a family history of ovarian cancer (ORidentified versus not identified: 3.11 [1.06 to 9.09]) (Table 
2). Further adjustment for gene revealed a significant association with age at menarche (ORidentified 
versus not identified: 2.99 [1.00 to 8.94]). There was also a trend between the likelihood of being identified 
as a carrier by selective testing and more children (Table 2). Tumors of BRCA1/2 carriers identified by 
selective testing were more often detected clinically (ORidentified versus not identified: 5.52 [1.38 to 22.18]), 
higher grade (ORidentified versus not identified: 0.28 [0.08 to 0.92]), larger size (ORidentified versus not identified: 2.48 
[1.00 to 6.16]) and of a basal subtype (ORidentified versus not identified: 6.07 [1.49 to 24.76]) (eTable 8 in Data 
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Supplement 1). The differences observed for all tumor characteristics and selective testing detection 
did not remain significant after adjusting for gene.  
DISCUSSION 
BRCA1/2 pathogenic variants were found in 1.8% of unselected breast cancer patients. In 
contrast to studies reporting BRCA1/2 prevalence for a subset of high risk women 27, 28, the present 
sample reflects the general breast cancer population. None of the breast cancer risk factors examined 
differed between BRCA1 and BRCA2 carriers. However, BRCA1 and BRCA2 breast cancers differed 
in the proportions of patients with ER-negative disease and basal-like subtype. Six out of ten 
BRCA1/2 carriers were not identified through genetic testing in the clinic.  
BRCA1 and BRCA2 mutation frequencies in breast and ovarian cancer patients unselected 
for family history or age at onset are generally low (<1–7% for BRCA1 and 1–3% for BRCA2) 29. The 
combined BRCA1/2 mutation frequency in a Swedish population of unselected breast cancer cases 
recruited from 1998 through 2000 in Stockholm has been previously estimated to be not more than 
1% in the work by Margolin et al. 1. In that study, screening for BRCA1 pathogenic variants was 
limited to exon 11, which covers over half the coding region of BRCA1 30. More than 70% of 
diagnosed pathogenic variants including four founder pathogenic variants in the Swedish population 
are known to be located on this exon 31-33. Prevalence of BRCA2 pathogenic variants in the Swedish 
population was deemed by Margolin et al. to be negligible among unselected breast cancer patients 
due to the low frequency of such pathogenic variants even in high-risk groups in the region 1. On the 
contrary, only 33 of 50 BRCA1 pathogenic variants were identified on exon 11 in this study, thus 
suggesting that 34% of BRCA1 carriers would have been missed if exon 11 alone were screened. 
Through testing the entire sequences of BRCA1/2 genes with improved methodology and techniques, 
we estimate the combined prevalence of BRCA1/2 pathogenic variants among unselected breast 
cancer patients in Sweden to be closer to 2%.  
There are close to 2,000 known BRCA1 germline pathogenic variants, many of which are 
loss-of-function frameshift pathogenic variants 34. Nine of 28 (32%) unique BRCA1 and 6 of 33 (18%) 
unique BRCA2 pathogenic variants were found to be recurrent in Swedish breast cancer patients (i.e. 
pathogenic variants that were found to occur in at least two unrelated individuals). The relatively low 
recurrent mutation frequency, including that of Swedish founder pathogenic variants, would mean that 
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screening of selected pathogenic variants alone may not be a sensitive approach in this population as 
majority of BRCA1 and BRCA2 carriers will have been missed. While BRCA1 pathogenic variants 
confer a more aggressive tumor phenotype, BRCA2 pathogenic variants typically resemble sporadic 
breast cancer 35. There is good agreement between our observed results regarding the tumor 
characteristic differences between BRCA1/2 and non-BRCA breast cancer cases and what has been 
previously reported in literature. It has been observed by others that tumors in BRCA1 carriers more 
frequently exhibited high mitotic count, high grade, ER and PR negativity 36-38. A large proportion of 
BRCA1 mutation cases (~80%) have also been documented to be triple negative and basal-like 
breast cancers 36-38. In a Swedish study where 54 female breast cancer patients from 22 families with 
BRCA2 germ line pathogenic variants from Sweden and Denmark were compared with 214 age- and 
date of diagnosis-matched controls identified among breast cancer patients from South Sweden, 
BRCA2-associated cases were more often node-positive than non-BRCA cases 39. Other than nodal 
involvement, BRCA2-associated breast carcinomas were generally associated with less aggressive 
tumor characteristics than BRCA1 cancers, and were more likely to be hormone-related 37, 38. 
Thirty-eight percent of BRCA1/2 carriers were identified through selective clinical testing of 
8.2% of breast cancer patients. Grindedal et al. evaluated the results of BRCA1/2 testing in South-
Eastern Norway and found that 65% of the BRCA1/2 carriers would have been missed if using age of 
onset below 40 or triple negative breast cancer as criteria for testing 40. It is also conceivable that, due 
to an emphasis on disease family history in current guidelines, a smaller family size may compromise 
the identification of high risk individuals who would otherwise benefit from genetic testing 41. In a 
Swedish retrospective study by Nilsson et al. where all breast cancer patients were tested, it was 
found that while 65% of the BRCA1/2 carriers fulfilled Swedish criteria for testing, only 18% had been 
identified in regular clinical routine 8. Other factors such as varying compliance with guidelines for the 
recommendation of BRCA testing by clinicians will lead to even more BRCA1/2 carriers being missed. 
It may thus be of benefit to test all newly diagnosed breast cancers in light of available targeted 
therapy options.  
To our knowledge, this is the largest population-based breast cancer testing study for 
BRCA1/2 published outside of founder populations. Despite the richness of the data which 
encompasses patient and tumor, some risk groups were too small to be examined with adequate 
statistical power (e.g. benign breast disease). The Swedish health care system is mainly government-
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funded and decentralized, making it possible to identify all women who went for clinical BRCA testing. 
Nonetheless, private health care also exists, and some BRCA1/2 carriers may have been identified by 
commercial testing outside the public sector. However, the number of patients tested outside of the 
national BRCA testing program is likely negligible during the period 2001-2008 8. It should be also 
noted that the Fluidigm Access Array method used cannot detect large rearrangements and has a 
sensitivity of ~90%, hence further analytical validity studies are needed. More sensitive methods and 
the universal BRCA testing of newly breast cancer patients will help to increase the number of women 
getting the best treatment for their disease.  
In summary, BRCA1/2 pathogenic variants were found in 1.8% of an unselected Swedish 
breast cancer cohort. Six out of ten BRCA carriers were not identified through selective clinical testing 
routines. Our results give fruitful information for further decisions of BRCA testing for all breast cancer 
patients at time of diagnosis. The presented data can be a starting point for further studies dealing 
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Figure 1. Mutation plots of BRCA1. Four and three splice variants for BRCA1 (NM_007294.3) are 
not shown. 
Figure 2. Mutation plots of BRCA2. Three splice variants for BRCA2 (NM_000059.3) are not shown. 
Figure 3. Overlap between women attending BRCA screening (clinically tested), BRCA carriers 
identified through selective clinical testing routine (clinically-detected carriers), and BRCA 
carriers identified through screening all unselected LIBRO1 breast cancer patients (unselected-
detected). Of the 416 women who were clinically tested, 39 were found to be BRCA1/2 carriers (39/416, 
9.3%). Our study confirmed 35 of these pathogenic variants. Four pathogenic variants were missed 
(BRCA1:  c.4186-1785_4358-1667dup and c.4358-1729_4986+736dup; BRCA2: 
c.7805+1538_8331+560del and c.9097_9098insT). By sequencing the entire Swedish study, we found 
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Table 1. Odds ratio (OR) and corresponding 95% confidence intervals (CI) of predictors according to BRCA status. 
 
BRCA1 vs non-BRCA 
OR (95% CI) 
BRCA2 vs non-BRCA 
OR (95% CI) 
BRCA2 vs BRCA1 
OR (95% CI) 
Model 1: Patient characteristics    
Age at diagnosis: 50-59 0.21 (0.10 to 0.45) 0.78 (0.36 to 1.69) 3.55 (1.05 to 11.97) 
Age at diagnosis: ≥60 0.14 (0.06 to 0.31) 0.55 (0.24 to 1.23) 3.91 (1.11 to 13.84) 
Year of diagnosis: 2005-2008 1.68 (0.91 to 3.08) 1.03 (0.55 to 1.92) 0.90 (0.33 to  2.48) 
HRT ever: Yes 1.08 (0.56 to 2.10 0.36 (0.17 to 0.76) 0.31 (0.10 to 0.93) 
Familiy history of breast cancer: Yes 3.57 (1.99 to 6.41) 2.08 (1.08 to 3.99) 0.60 (0.24 to 1.55) 
Familiy history of ovarian cancer: Yes 6.99 (3.43 to 14.24) 3.57 (1.47 to 8.68) 0.38 (0.11 to 1.35) 
Personal history of ovarian cancer: Yes 19.21 (5.89 to 62.72) 8.01 (1.61 to 39.94) 0.49 (0.04 to 6.74) 
Personal history of any malignant cancer (not breast): Yes 1.35 (0.52 to 3.54) 0.81 (0.26 to 2.56) 0.49 (0.07 to 3.59) 
    
Model 2: Tumor characteristics, adjusted for age and year of diagnosis    
Detection mode: Interval 1.34 (0.38 to 4.79) 1.16 (0.45 to 3.03) 0.44 (0.05 to 3.50) 
Detection mode: Clinical cancer in women without previous mammograms  2.61 (0.81 to 8.37) 0.66 (0.20 to 2.12) 0.35 (0.05 to 2.38) 
Detection mode: Clinical cancer in women who had previous mammograms (i.e. interval >24 months)   3.54 (1.15 to 10.89) 1.57 (0.63 to 3.94) 0.34 (0.06 to 2.02) 
ER status: Negative 5.19 (2.68 to 10.06) 1.17 (0.48 to 2.87) 0.22 (0.07 to 0.77) 
Grade: Intermediate-differentiated 1.97 (0.24 to 16.23) 1.82 (0.52 to 6.34) 1.32 (0.10 to 18.26) 
Grade: Poorly-differentiated 7.11 (0.91 to 55.30) 1.55 (0.39 to 6.22) 0.36 (0.03 to 4.92) 
Tumor size: ≥20 0.87 (0.48 to 1.59) 1.26 (0.67 to 2.39) 1.17 (0.37 to 3.76) 
Nodal involvement: Yes 1.60 (0.79 to 3.27) 2.54 (1.20 to 5.37) 1.67 (0.43 to 6.51) 
    
Model 3: Breast cancer subtype, adjusted for age and year of diagnosis    
Subtype: Luminal B 2.83 (0.54 to 14.77) 0.49 (0.06 to 3.73) 0.19 (0.01 to 2.60) 
Subtype: HER2-enriched 0.93 (0.11 to 8.07) 0.33 (0.04 to 2.52) 0.38 (0.02 to 8.07) 
Subtype: Basal-like 40.07 (14.26 to 112.59) 0.84 (0.11 to 6.43) 0.02 (0.00 to 0.17) 
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Table 2. Frequency, odds ratio (OR) and corresponding 95% confidence intervals (CI) of patient 
characteristics among BRCA carriers identified versus not identified through selective clinical screening.  
* Adjusted for year of diagnosis (2001-2004, 2005-2008). † Adjusted for year of diagnosis and gene (BRCA1, 
BRCA2). ‡ Adjust for year of diagnosis, gene and age at diagnosis (<50, 50-59, ≥60). 
Patient characteristic 








OR (95% CI)* OR (95% CI)† OR (95% CI)‡ 
Gene, *unadjusted      
BRCA1 23 (40.4) 27 (77.1) 1.00 (Reference)   
BRCA2 34 (59.6) 8 (22.9) 0.20 (0.08 to 0.52)   
      
Age at diagnosis, *unadjusted      
<50 15 (26.3) 22 (62.9) 1.00 (Reference)   
50-59 20 (35.1) 8 (22.9) 0.27 (0.10 to 0.78)   
≥60 22 (38.6) 5 (14.3) 0.15 (0.05 to 0.50)   
      
Year of diagnosis, *unadjusted      
2001-2004 26 (45.6) 12 (34.3) 1.00 (Reference)   
2005-2008 31 (54.4) 23 (65.7) 1.61 (0.67 to 3.84)   
      
Education      
University 29 (50.9) 21 (60.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Intermediate 12 (21.1) 9 (25.7) 1.06 (0.37 to 2.98) 1.40 (0.45 to 4.39) 2.08 (0.59 to 7.40) 
 Elementary 7 (12.3) 0 (0.0) - - - 
Other 9 (15.8) 5 (14.3) 0.78 (0.23 to 2.68) 0.65 (0.17 to 2.46) 1.63 (0.35 to 7.66) 
       
Age at menarche in years      
<13 21 (36.8) 7 (20.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
≥13 36 (63.2) 28 (80.0) 2.17 (0.79 to 5.94) 2.99 (1.00 to 8.94) 4.12 (1.19 to 14.26) 
       
Menopause status before breast cancer diagnosis      
Premenopause 14 (24.6) 23 (65.7) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Postmenopause 43 (75.4) 12 (34.3) 0.17 (0.07 to 0.44) 0.17 (0.06 to 0.45) 0.18 (0.03 to 1.25) 
       
BMI in kg/m2      
<25 29 (50.9) 24 (68.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
≥25 27 (47.4) 11 (31.4) 0.52 (0.21 to 1.27) 0.42 (0.16 to 1.12) 0.32 (0.11 to 0.94) 
 Missing 1 (1.8) 0 (0.0)    
      
Percentage mammographic density      
<25 22 (38.6) 10 (28.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
≥25 16 (28.1) 14 (40.0) 1.97 (0.69 to 5.62) 1.54 (0.51 to 4.69) 0.93 (0.27 to 3.21) 
 Missing 19 (33.3) 11 (31.4)    
      
Number of children      
0 12 (21.1) 3 (8.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
1 13 (22.8) 7 (20.0) 2.39 (0.49 to 11.65) 2.64 (0.50 to 13.83) 5.34 (0.84 to 33.79) 
2 22 (38.6) 14 (40.0) 2.91 (0.68 to 12.53) 3.12 (0.68 to 14.24) 4.76 (0.89 to 25.43) 
≥3 10 (17.5) 11 (31.4) 4.64 (1.00 to 21.66) 4.69 (0.93 to 23.60) 10.55 (1.62 to 68.68) 
      
HRT ever      
No 34 (59.6) 25 (71.4) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Yes 21 (36.8) 10 (28.6) 0.61 (0.24 to 1.54) 0.45 (0.16 to 1.24) 0.84 (0.26 to 2.70) 
 Missing 2 (3.5) 0 (0.0)    
      
Oral contraceptives ever      
No 19 (33.3) 5 (14.3) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Yes 37 (64.9) 30 (85.7) 3.04 (1.01 to 9.15) 2.90 (0.91 to 9.24) 2.36 (0.71 to 7.85) 
 Missing 1 (1.8) 0 (0.0)    
      
Family history of breast cancer      
No 37 (64.9) 18 (51.4) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Yes 20 (35.1) 17 (48.6) 1.84 (0.77 to 4.39) 1.58 (0.63 to 3.99) 1.46 (0.54 to 3.90) 
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Family history of ovarian cancer      
No 50 (87.7) 24 (68.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Yes 7 (12.3) 11 (31.4) 3.11 (1.06 to 9.09) 2.87 (0.91 to 9.11) 3.41 (0.99 to 11.73) 
       
Ovarian cancer      
No 51 (89.5) 33 (94.3) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Yes 6 (10.5) 2 (5.7) 0.60 (0.11 to 3.26) 0.37 (0.06 to 2.17) 0.46 (0.07 to 3.01) 
       
Other malignant cancer      
No 48 (84.2) 31 (88.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
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eTable 1. Exclusion criteria for genotyping experiment (Michailidou et al. 1). Of the 5,715 women who consented to 
genetic analyses of their blood samples, genotyping was successfully performed for 5,125 women. Of these, 5,122 
had enough DNA remaining for targeted sequencing.  
 
Exclusion criteria for genotyping experiment n 
Concordant replicate - exclude lower call rate 116 
Cryptic Duplicate 7 
Extreme heterozygous 34 
Call rate (<95%) 8 
Male 1 
Non-European 114 
Phenotype data excluded 177 
Relative pairs with different status 9 
Relative pairs, exclude lower call rate 39 
Unclear whether consented when data released in Jan 2012 69 
Study duplicates with KARBAC sample 4 






Details on targeted sequencing methodology used by the University of Cambridge (Fluidigm Access Array 
method) 
Targeted sequencing 
Target-enriched sequencing libraries of germline DNA from 5,122 breast cancer patients were prepared at the 
Centre for Cancer Genetic Epidemiology (University of Cambridge). Data used in this study were part of a larger effort 
that included samples from other cohorts, as well as coding sequences and intron/exon boundaries for a total of 31 
known or suspected breast cancer susceptibility genes, including BRCA1 and BRCA2. Assay design was conducted 
as previously described 2. See eTable 2 (Data Supplement 2) for primer sequences and amplicon details. 
Briefly, target sequence enrichment was performed using 48.48 Fluidigm Access Arrays according to the 
manufacturer’s protocol (Fluidigm, South San Francisco, California, USA). Fluidigm D3 assay design software was 
used to select primer pairs, which were multiplexed into pools selected for GC content and avoidance of off-target 
primer-primer and primer-product complementarity. Target sequences were amplified with Illumina sequencing 
adaptors and one of 1,536 unique sample barcodes (supplied by Fluidigm, South San Francisco, California, USA). 
Robotic liquid handling and barcode plate identification were used in all steps of the library preparation process. Each 
library of amplicons (eTable 2, Data Supplement 2)  for 1,536 samples was quantified with the KAPA Library 
Quantification Kit (KapaBiosystems, Boston, Massachusetts, USA) and then sequenced on the Illumina Hi-Seq 2500 
instrument using v4 chemistry, according to the manufacturer’s protocol (Illumina, San Diego, California, USA). Each 
library was sequenced 2-3 times to provide sufficient coverage.  
 Sequence data processing and quality control 
Raw data in FASTQ format was received from the University of Cambridge. Paired-end sequencing reads 
were aligned to the  human genome reference sequence (hg19) using Burrows-Wheeler Aligner (version 0.7.12 3). 
Aligned reads in SAM format were converted to BAM format and subsequently merged for each sample using 
SAMtools (version 1.1 4). Read groups were assigned using Picard (version 1.119; 
http://broadinstitute.github.io/picard). Genome Analysis Toolkit (GATK version 3.7.0;  
https://software.broadinstitute.org/gatk/) was used for local insertion/deletion (indel) realignment and base quality 
score recalibration, variant calling, SNP and indel parsing and for deriving quality and depth metrics 5. The mean read 
depth across the coding sequences of BRCA1 and BRCA2 was 792.2 (standard deviation: 587.4) and 631 (standard 
deviation: 516), respectively. More than 90% of targeted bases had more than 15x coverage (94.8 [15.9] and 92.5 
[20.4] for BRCA1 and BRCA2, respectively).  
Genetic variants were called with Unified Genotyper using the default parameters except –mindelFrac 0.05. 
SNPs and indels with low variant confidence/quality by depth (QD<2) and low approximate read depth (DP<10) were 
removed. Filter-based annotation of variants were performed using ANNOVAR 6. A total of 5,099 samples with valid 
variant calls were included in the final analytical dataset. 
 
Details on targeted sequencing methodology used by the Department of Oncology, Lund University (modified 
SureSelect hybrid selection method) 
The clinical mutation screening was performed using the most sensitive methods available for comprehensive 
detection of all classes of genetic variants known to affect BRCA1 and BRCA2. Targeted sequencing libraries were 
prepared using a modified SureSelect hybrid selection method and a custom panel targeting 64 genes including 
complete BRCA1 and BRCA2 loci (exons and introns) and 100kb up- and downstream. Specificity was ensured by 
confirming all variants with Sanger sequencing on an independent DNA extraction from the patient blood sample. 
Paired-end sequencing of the libraries was performed on a HiSeq 2500 (2x100bp) to an average depth of ~400 reads. 
Until 2016, this was complemented with multiple ligation-dependent probe amplification (MLPA) for detection of 
deletions and duplications affecting one or more complete exons. The lab now has validated bioinformatic methods for 
detecting these variants directly from the sequencing data. Sensitivity estimated using a large collection of positive 
control samples including all classes of known pathogenic variants is 100%. Before 2010, denaturing high 
performance liquid chromatography (DHPLC) and MLPA was used. Together, the DHPLC and MLPA have a stated 









Three cases of breast cancer in first degree relatives, or second degree relatives thought a male, with at 
least one diagnosed ≤50y, and/or ovarian cancer (regardless of age) 
79 
Two cases of breast cancer or ovarian cancer in first degree relatives, or second degree relatives 
thought a male, with at least one case of breast cancer diagnosed ≤40y, or two cases of ovarian cancer 
(regardless of age) 
113 
One case of breast cancer ≤35y 99 
One case of triple-negative breast cancer ≤40y 20 
One case of male breast cancer NA 
Breast cancer and ovarian cancer in one individual 44 
Cases of bilateral breast cancer, prostate cancer, and pancreatic cancer may strengthen the indication 






eTable 4. Description of BRCA1 (NM_007294.3) pathogenic variants. 
Exon cDNA Change AA Change Variant Classification BIC Nomenclature Note n 
2 c.68_69delAG p.E23fs frameshift deletion 185_186delAG,185delAG,187delAG Founder mutation in Ashkenazi Jews 7 3 
5 c.181T>G p.C61G nonsynonymous SNV 300T>G Common mutation in Europe 8 1 
7 c.302-2A>G - splice site - - 1 
11 c.930delG p.Q310fs frameshift deletion 1049delG - 1 
11 c.962G>A p.W321* stopgain W321X - 1 
11 c.1082_1092delCAGAGAATCCT p.S361* stopgain 1201del11 Founder mutation common in Southern Sweden 9 5 
11 c.1360_1361delAG p.S454* stopgain 1479delAG - 3 
11 c.1504_1508delTTAAA p.L502fs frameshift deletion 1623_1627delTTAAA - 1 
11 c.1772delT p.I591fs frameshift deletion 1891delT - 1 
11 c.1961delA p.K654fs frameshift deletion 2080delA - 1 
11 c.2184delA p.E729fs frameshift deletion - - 1 
11 c.2475delC p.D825fs frameshift deletion 2594delC Swedish BRCA1 founder mutation 10 2 
11 c.3048_3052dupTGAGA p.N1018fs frameshift insertion 3166insTGAGA, p.Asn1018fs Founder mutation originating from West Coast of Sweden 8, 11 8 
11 c.3178G>T p.E1060* stopgain E1060X - 1 
11 c.3485delA p.D1162fs frameshift deletion 3604delA Founder mutation in Finland 8 1 
11 c.3607C>T p.R1203* stopgain 3726C>T - 1 
11 c.3626delT p.L1209* stopgain 3745delT Founder mutation originating in Northern Sweden 8 3 
11 c.3700_3704delGTAAA p.V1234fs frameshift deletion 3819_3823delGTAAA Frequent mainly in Middle and Eastern Europe and Canada 12 1 
11 c.4035delA p.E1346fs frameshift deletion 4154delA Common mutation in Poland and Latvia 8 2 
13 c.4201C>T p.Q1401* stopgain - - 1 
13 c.4327C>T p.R1443* stopgain 4446C>T - 1 
17 c.5030_5033delCTAA p.T1677fs frameshift deletion 5149del4,5147del4,5146del4 - 1 
18 c.5075-2A>C - splice site IVS17-2A>C - 1 
18 c.5095C>T p.R1699W nonsynonymous SNV 5214C>T - 1 
18 c.5123C>A p.A1708E nonsynonymous SNV 5242C>A - 1 
19 c.5153-1G>C - splice site IVS18-1G>C - 2 
20 c.5266dupC p.Q1756fs frameshift insertion 5382_5383insC,5382insC,5383insC,5384insC,5385insC Founder mutation in Russia 13 3 
21 c.5278-2A>T - splice site - - 1 
 
 
eTable 5. Description of BRCA2 (NM_000059.3) pathogenic variants. 
Exon cDNA Change AA Change Variant Classification BIC Nomenclature Note n 
10 c.805dupA p.T269fs frameshift insertion 1033insA,p.Thr269fs - 1 
10 c.1310_1313delAAGA p.K437fs frameshift deletion 1537_1540delAAAG - 1 
10 c.1796_1800delCTTAT p.S599* stopgain 2024_2028delCTTAT -  1 
10 c.1813dupA p.I605fs frameshift insertion 2041_2042insA - 1 
11 c.2179delT p.S727fs frameshift deletion - - 1 
11 c.2376C>G p.Y792* stopgain - -  1 
11 c.2476G>T p.E826* stopgain - - 1 
11 c.2578delA p.I860fs frameshift deletion - - 1 
11 c.2808_2811delACAA p.A938fs frameshift deletion 3036_3039delACAA - 1 
11 c.3157_3163delTTAGATA p.L1053fs frameshift deletion - - 1 
11 c.3283C>T p.Q1095* stopgain - - 2 
11 c.3847_3848delGT p.V1283fs frameshift deletion 4075_4076delGT - 1 
11 c.3860delA p.N1287fs frameshift deletion 4088delA,4082delA - 1 
11 c.3950delC p.T1317fs frameshift deletion - - 1 
11 c.5073delA p.K1691fs frameshift deletion 5301delA - 3 
11 c.5754_5755delTA p.H1918fs frameshift deletion - - 2 
11 c.5823delA p.V1942fs frameshift deletion 6051delA - 1 
11 c.5946delT p.S1982fs frameshift deletion 6174delT Founder mutation in Ashkenazi Jews 8 4 
11 c.6444delT p.I2149fs frameshift deletion - - 1 
11 c.6486_6489delACAA p.K2162fs frameshift deletion 6714_6717delACAA - 2 
14 c.7097dupT p.T2367fs frameshift insertion - - 1 
14 c.7414_7415delAA p.K2472fs frameshift deletion 7642delAA - 1 
15 c.7443delT p.T2482fs frameshift deletion 7671delT -  1 
15 c.7480C>T p.R2494* stopgain 7708C>T - 1 
15 c.7558C>T p.R2520* stopgain 7786C>T - 1 
16 c.7618-1G>A - splice site IVS15-1G>A - 1 
17 c.7974C>G p.Y2658* stopgain Y2658X - 1 
19 c.8332-1G>A - splice site - - 1 
20 c.8513T>G p.L2838* stopgain 8741T>G, p.Leu2838X - 1 
22 c.8910G>A p.W2970* stopgain 9138G>A (W-X),p.Trp2970X - 1 
23 c.9097delA p.T3033fs frameshift deletion - - 2 
24 c.9118-2A>G - splice site IVS23-2A>G - 1 
25 c.9403delC p.L3135fs frameshift deletion 9631delC - 1 
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eTable 6. Frequency, odds ratio (OR) and corresponding 95% confidence intervals (CI) of patient characteristics 
according to BRCA status. *Adjusted for age (<50, 50-59, ≥60) and year of diagnosis (2001-2004 and 2005-2008). 
 





BRCA1 vs non-BRCA 
OR (95% CI)* 
BRCA2 vs  
non-BRCA 
OR (95% CI)* 
BRCA2 vs BRCA1 
OR (95% CI)* 
Age at study entry, years (mean, SD) 63.4 (9.9) 54.9 (12.6) 58.6 (9.4)    
       
Age at diagnosis, years (mean, SD) 58.6 (9.9) 50.3 (12.4) 54.0 (9.5)    
       
Age at diagnosis, years (unadjusted)       
   <50 887 (17.7) 24 (48.0) 13 (31.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   50-59 1666 (33.3) 13 (26.0) 15 (35.7) 0.29 (0.15 to 0.57) 0.61 (0.29 to 1.30) 2.13 (0.78 to 5.81) 
   ≥60 2454 (49.0) 13 (26.0) 14 (33.3) 0.20 (0.10 to 0.39) 0.39 (0.18 to 0.83) 1.99 (0.72 to 5.47) 
       
Year of diagnosis (unadjusted)       
   2001-2004 2325 (46.4) 19 (38.0) 19 (45.2) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   2005-2008 2682 (53.6) 31(62.0) 23 (54.8) 1.41 (0.80 to 2.51) 1.05 (0.57 to 1.93) 0.74 (0.32 to 1.71) 
       
Education       
   University 2113 (42.2) 29 (58.0) 21 (50.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Intermediate 1116 (22.3) 9 (18.0) 12 (28.6) 0.60 (0.28 to 1.27) 1.09 (0.53 to 2.23) 1.51 (0.52 to 4.42) 
   Elementary 753 (15.0) 3 (6.0) 4 (9.5) 0.48 (0.14 to 1.63) 0.66 (0.22 to 1.96) 1.10 (0.20 to 6.02) 
   Other 961 (19.2) 9 (18.0) 5 (11.9) 1.05 (0.48 to 2.29) 0.63 (0.23 to 1.72) 0.50 (0.13 to 1.89) 
   Missing 64 (12.8) 0 (0.0) 0 (0.0)    
       
Age at menarche, years       
   <13 1592 (31.8) 17 (34.0) 11 (26.2) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   ≥13 3263 (65.2) 33 (66.0) 31 (73.8) 1.12 (0.62 to 2.03) 1.52 (0.76 to 3.06) 1.51 (0.58 to 3.89) 
   Missing 152 (3.0) 0 (0.0) 0 (0.0)    
       
BMI, kg/m2       
   <25 2644 (52.8) 28 (56.0) 25 (59.5) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   ≥25 2275 (45.4) 22 (44.0) 16 (38.1) 1.03 (0.58 to  1.81) 0.79 (0.42 to  1.49) 0.84 (0.35 to 2.00) 
   Missing 88 (1.8) 0 (0.0) 1 (2.4)    
       
Percentage mammographic density       
   <25 2362 (47.2) 15 (30.0) 17 (40.5) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   ≥25 1507 (30.1) 20 (40.0) 10 (23.8) 1.34 (0.66 to 2.75) 0.73 (0.32 to 1.65) 0.52 (0.18 to 1.53) 
   Missing 1138 (22.7) 15 (30.0) 15 (35.7)    
       
Number of children       
   0 814 (16.3) 8 (16.0) 7 (16.7) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   1 887 (17.7) 10 (20.0) 10 (23.8) 1.26 (0.49 to  3.21) 1.37 (0.52 to  3.62) 0.96 (0.24 to 3.85) 
   2 2145 (42.8) 19 (38.0) 17 (40.5) 0.98 (0.43 to  2.26) 0.96 (0.40 to  2.33) 0.95 (0.27 to 3.31) 
   ≥3 1130 (22.6) 13 (26.0) 8 (19.0) 1.36 (0.56 to  3.31) 0.89 (0.32 to  2.48) 0.64 (0.16 to 2.54) 
   Missing 31 (0.6) 0 (0.0) 0 (0.0)    
       
HRT ever       
   No 2208 (44.1) 30 (60.0) 29 (69.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 2694 (53.8) 20 (40.0) 11 (26.2) 1.02 (0.53 to 1.94) 0.36 (0.17 to 0.75) 0.36 (0.13 to 1.00) 
   Missing 105 (2.1) 0 (0.0) 2 (4.8)    
       
Oral contraceptives ever       
   No 1285 (25.7) 11 (22.0) 13 (31.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 3663 (73.2) 39 (78.0) 28 (66.7) 0.87 (0.43 to 1.75) 0.58 (0.29 to 1.16) 0.67 (0.26 to 1.75) 
   Missing 59 (1.1) 0 (0.0) 1 (2.4)    
       
Ovarian cancer       
   No 4971 (99.3) 44 (88.0) 40 (95.2) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 36 (0.7) 6 (12.0) 2 (4.8) 28.02 (10.72 to 73.29) 8.11 (1.87 to 35.24) 0.27 (0.05 to 1.50) 
       
Any malignant cancer, not breast       
   No 4494 (89.8) 41 (82.0) 38 (90.5)    
   Yes 513 (10.2) 9 (18.0) 4 (9.5) 2.93 (1.37 to 6.27) 1.12 (0.39 to 3.20) 0.39 (0.10 to 1.44) 





Family history of breast cancer       
   No 3948 (78.8) 27 (54.0) 28 (66.7) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 916 (18.3) 23 (46.0) 14 (33.3) 4.00 (2.27 to 7.05) 2.23 (1.17 to 4.26) 0.60 (0.25 to 1.43) 
   Missing 143 (2.9) 0 (0.0) 0 (0.0)    
       
Family history of ovarian cancer       
   No 4753 (94.9) 38 (76.0) 36 (85.7) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 231 (4.6) 12 (24.0) 6 (14.3) 7.53 (3.82 to 14.82) 3.62 (1.50 to 8.71) 0.52 (0.17 to 1.61) 
   Missing 23 (0.5) 0 (0.0) 0 (0.0)    
       
Breast cancer in mother       
   No 4392 (87.7) 29 (58.0) 32 (76.2) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 579 (11.6) 21 (42.0) 10 (23.8) 5.17 (2.92 to  9.17) 2.29 (1.12 to  4.68) 0.47 (0.18 to 1.20) 
   Missing 36 (0.7) 0 (0.0) 0 (0.0)    
       
Age at breast cancer diagnosis in mother        
   <50 92 (15.9) 11 (52.4) 4 (40.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   ≥59 446 (77.0) 9 (42.9) 6 (60.0) 0.20 (0.08 to 0.50) 0.37 (0.10 to  1.35) 2.05 (0.39 to  10.67) 
   Missing 43 (7.4) 1 (4.8) 0 (0.0)    
       
Ovarian cancer in mother       
   No 4822 (96.3) 39 (78.0) 36 (85.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 149 (3.0) 11 (22.0) 6 (14.3) 9.82 (4.85 to  19.89) 5.44 (2.24 to  13.18) 0.61 (0.20 to 1.86) 
   Missing 36 (0.7) 0 (0.0) 0 (0.0)    
       
Ovarian cancer in sister       
   No 4885 (97.6) 48 (96.0) 42 (100.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 86 (1.7) 2 (4.0) 0 (0.0) 3.23 (0.76 to  13.76) - - 
   Missing 36 (0.7) 0 (0.0) 0 (0.0)    
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eTable 7. Frequency, odds ratio (OR) and corresponding 95% confidence intervals (CI) of tumor characteristics 











BRCA1 vs  
non-BRCA 
OR (95% CI)* 
BRCA2 vs 
 non-BRCA 
OR (95% CI)* 
BRCA2 vs  
BRCA1 
OR (95% CI)* 
Type of breast cancer       
   Invasive 4470 (89.3) 48 (96.0) 42 (100.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Non-invasive 522 (10.4) 2 (4.0) 0 (0.0) 0.37 (0.09 to  1.53) - - 
   Missing 15 (0.3) 0 (0.0) 0 (0.0)    
       
Detection mode       
   Screen-detected 1844 (36.8) 5 (10.0) 12 (28.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Interval 768 (15.3) 5 (10.0) 7 (16.7) 2.36 (0.68 to  8.17) 1.39 (0.54 to  3.54) 0.63 (0.12 to 3.20 
   Clinical cancer in women without 
   previous mammograms  911 (18.2) 8 (16.0) 4 (9.5) 3.99 (1.26 to 12.66) 0.76 (0.24 to  2.43) 0.22 (0.04 to 1.08) 
   Clinical cancer in women who had 
   previous mammograms (i.e. interval >24 months)   1395 (27.9) 31 (62.0) 19 (45.2) 5.20 (1.78 to 15.15) 1.77 (0.73 to  4.29) 0.35 (0.08 to 1.49) 
   Missing 89 (1.8) 1 (2.0) 0 (0.0)    
       
Estrogen receptor status       
     Positive 3637 (72.6) 17 (34.0) 30 (71.4) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     Negative 643 (12.8) 30 (60.0) 7 (16.7) 8.98 (4.90 to 16.46) 1.23 (0.54 to  2.82) 0.14 (0.05 to 0.39) 
     Missing 727 (14.5) 3 (6.0) 5 (11.9)    
       
Progesterone receptor status       
     Positive 2952 (59.0) 14 (28.0) 24 (57.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     Negative 1252 (25.0) 33 (66.0) 13 (31.0) 6.06 (3.21 to 11.46) 1.33 (0.67 to  2.63) 0.23 (0.09 to 0.60) 
     Missing 803 (16.0) 3 (6.0) 5 (11.9)    
       
Grade       
     Well-differentiated 578 (11.5) 1 (2.0) 3 (7.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     Moderately differentiated 1563 (31.2) 7 (14.0) 16 (38.1)  2.41 (0.30 to  19.66)  1.91 (0.55 to   6.60) 0.80 (0.07 to  9.47) 
     Poorly differentiated 822 (16.4) 31 (62.0) 9 (21.4) 17.99 (2.44 to 132.70)  1.90 (0.51 to   7.10) 0.11 (0.01 to  1.22) 
     Missing 2044 (40.8) 11 (22.0) 14 (33.3)    
       
Tumor size (mm)       
     <20 3020 (60.3) 27 (54.0) 23 (54.8) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     ≥20 1608 (32.1) 21 (42.0) 19 (45.2) 1.30 (0.73 to 2.32) 1.47 (0.80 to 2.72) 1.16 (0.46 to 2.89) 
     Missing 379 (7.6) 2 (4.0) 0 (0)    
       
Nodal involvement       
     No 4503 (89.9) 39 (78.0) 32 (76.2) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     Yes 466 (9.3) 11 (22.0) 10 (23.8) 2.08 (1.04 to  4.14) 2.71 (1.31 to  5.62) 1.27 (0.46 to 3.54) 
     Missing 38 (0.8) 0 (0.0) 0 (0.0)    
       
Proliferation level (Ki67)       
     Low (<20%) 923 (18.4) 5 (10.0) 11 (26.2) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     High (≥20%) 736 (14.7) 20 (40.0) 7 (16.7) 4.25 (1.58 to 11.44) 0.72 (0.28 to  1.88) 0.18 (0.04 to  0.74) 
     Missing 3348 (66.9) 25 (50.0) 24 (57.1)    
       
Molecular subtypes       
     Luminal A 1212 (24.2) 5 (10.0) 15 (35.7) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     Luminal B 156 (3.1) 2 (4.0) 1 (2.4) 2.83 ( 0.54 to  14.77) 0.49 ( 0.06 to   3.73) 0.19 (0.01 to  2.60) 
     HER2-enriched 214 (4.3) 1 (2.0) 1 (2.4) 0.93 ( 0.11 to   8.07) 0.33 ( 0.04 to   2.52) 0.38 (0.02 to  8.07) 
     Basal-like 84 (1.7) 17 (34.0) 1 (2.4) 40.07 (14.26 to 112.59) 0.84 ( 0.11 to   6.43) 0.02 (0.00 to  0.17) 




eTable 8. Frequency, odds ratio (OR) and corresponding 95% confidence intervals (CI) of tumor characteristics 
among BRCA carriers identified versus not identified through selective clinical screening. * Adjusted for year of 
diagnosis (2001-2004, 2005-2008). † Adjusted for year of diagnosis and gene (BRCA1, BRCA2). ‡ Adjust for year of 
diagnosis, gene and age at diagnosis (<50, 50-59, ≥60). 
Tumor characteristic 








OR (95% CI)* OR (95% CI)† OR (95% CI)‡ 
      
Type of breast cancer      
   Invasive 56 (98.2) 34 (97.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Non-invasive 1 (1.8) 1 (2.9) 2.27 (0.13 to 39.73) 1.11 (0.06 to 20.11) 1.44 (0.06 to 37.74) 
       
Detection mode      
   Screen-detected 14 (24.6) 3 (8.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Interval 8 (14.0) 4 (11.4) 2.56 (0.44 to 14.85) 2.24 (0.34 to 14.73) 1.56 (0.21 to 11.33) 
   Clinical cancer in women without previous mammograms  10 (17.5) 2 (5.7) 0.79 (0.11 to 5.72) 0.41 (0.05 to 3.37) 0.48 (0.06 to 4.06) 
   Clinical cancer in women who had previous mammograms  
      
24 (42.1) 26 (74.3) 5.52 (1.38 to 22.18) 3.85 (0.88 to 16.87) 1.88 (0.32 to 11.01) 
   Missing 1 (1.8) 0 (0.0)    
      
Estrogen receptor      
   Positive 34 (59.6) 13 (37.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Negative 19 (33.3) 18 (51.4) 2.48 (0.99 to 6.19) 1.29 (0.45 to 3.68) 0.81 (0.25 to 2.63) 
   Missing 4 (7.0) 4 (11.4)    
      
Progesterone receptor      
   Positive 25 (43.9) 13 (37.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Negative 27 (47.4) 19 (54.3) 1.30 (0.53 to 3.19) 0.69 (0.24 to 1.97) 0.46 (0.14 to 1.52) 
   Missing 5 (8.8) 3 (8.6)    
      
Grade      
   Poorly-differentiated  20 (35.1) 20 (57.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Intermediate-differentiated 18 (31.6) 5 (14.3) 0.28 (0.08 to 0.92) 0.48 (0.13 to 1.78) 0.67 (0.17 to 2.70) 
    Well-differentiated 4 (7.0) 0 (0.0) -  - 
   Missing 15 (26.3) 10 (28.6)    
      
Tumor size (mm)      
    <20 35 (61.4) 15 (42.9) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
    ≥20 16 (28.1) 17 (48.6) 2.48 (1.00 to 6.16) 2.91 (1.07 to 7.92) 2.15 (0.74 to 6.24) 
    Missing 5 (8.8) 2 (5.7)    
      
Nodal involvement      
   No 45 (78.9) 26 (74.3) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Yes 12 (21.1) 9 (25.7) 1.40 (0.51 to 3.84) 1.53 (0.52 to 4.52) 1.15 (0.36 to 3.67) 
       
Proliferation level (Ki67)      
     Low (<20%) 11 (19.3) 5 (14.3) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     High (≥20%) 12 (21.1) 15 (42.9) 2.75 (0.75 to 10.11) 
 
1.55 (0.37 to 6.43) 0.80 (0.16 to 3.96) 
      Missing 34 (59.6) 15 (42.9)    
      
Molecular subtypes      
     Luminal A 14 (24.6) 6 (17.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
     Luminal B 2 (3.5) 1 (2.9) 1.17 (0.09 to 15.46) 0.65 (0.04 to 9.93) 0.37 (0.02 to 6.64) 
      HER2-enriched 2 (3.5) 0 (0.0) - - - 
     Basal-like 5 (8.8) 13 (37.1) 6.07 (1.49 to 24.76) 2.54 (0.52 to 12.41) 1.49 (0.25 to 8.76) 
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eTable 2. Primer sequences and amplicon details. Partially overlapping amplicons were tiled across the target regions with a maximum amplicon length (forward and reverse 
primer length plus intervening unique sequence) of 200-bp. Primers were designed with melting temperature range 59.0-61.0  ̊C. Each primer included an orientation-specific 
tail sequence for subsequent ligation of adapter and barcode sequences. 
Gene/Chr 
Assay 
Name Chr Start End Forward primer Reverse primer 
Total 
amplicon 
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AA 188 36 
TGCTACTCTCTACAGATCTTTCAGTTTGCAAAACCCTTTCTCCACTTAACA
TGAGATCTTTGGGGTCTTCAGCATTATTAGACACTTTAACTGTTTCTAGTT
Assays designed by 














Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 




















Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 


































































































































































































































































































































































































































































































































































































































































Assays designed by 
relax mode and have no 
off-target hits 























































































































One primer sits in the 
repeat region 











Assays designed by 
relax mode and have no 
off-target hits 



















Assays designed by 
relax mode and have no 
off-target hits 






























Assays designed by 
relax mode and have no 
off-target hits 








































































































Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 





















Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 









One primer sits in the 
repeat region 











Assays designed by 
relax mode and have no 
off-target hits 





















Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 





TCTGCATTCCTCAGAAGTGGTC 178 35 
AATTTAACACCTAGCCAAAAGGCAGAAATTACAGAACTTTCTACTATATTA
GAAGAATCAGGAAGTCAGTTTGAATTTACTCAGTTTAGAAAACCAAGCTA
Assays designed by 














Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 






TAGAGGGAGA 171 29 
ATTTCTTTTTAGGAGAACCCTCAATCAAAAGAAACTTATTAAATGAATTTG
ACAGGATAATAGAAAATCAAGAAAAATCCTTAAAGGCTTCAAAAAGCACT
Assays designed by 













Assays designed by 
relax mode and have no 
off-target hits 





















Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 






















Assays designed by 
relax mode and have no 
off-target hits 





















Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 
















AGAGGAAAAGGTCTAGGGTCAG 194 32 
TTTTTAAAGTGAATATTTTTAAGGCAGTTCTAGAAGAATGAAAACTCTTAT
GATATCTGTAATAGAATTGAATACATATTTAACTACTAAATCAATATATTTA
Assays designed by 














Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 




















Assays designed by 
relax mode and have no 
off-target hits 





















Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 











Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 














































































































































































































Assays designed by 











































































































































































One primer sits in the 
repeat region 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 































Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 












Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 










Assays designed by 
relax mode and have no 
off-target hits 




















Assays designed by 


























































































































































































CGTTTCCTTGCTTGAAAAA 168 50 
GTTGCGGTGAGCGGAGATTGCGCCATTGCACACCAGCCCGGGCCACAA
GAGCGAAACTCCGTCTCAAAAAAAAAAGCAAAAGATACTACCAAGCCCT
GCGGAGCAAGGTACCTCACACTTCATGAGCGAGTTAAGATGGGTTTCAC
AATTTTTCAAGCAAGGAAACGG  
 



